<DOC>
	<DOC>NCT00367315</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of using lumiracoxib in the treatment of patients with knee osteoarthritis (OA)</brief_summary>
	<brief_title>Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Primary osteoarthritis of knee (confirmed by American College of Rheumatology [ACR] criteria). Requirement of regular nonsteroidal antiinflammatory drug (NSAID) therapy. Evidence of active peptic ulceration within 12 months prior to the screening visit or history of active gastrointestinal bleeding within the previous 5 years. Known hypersensitivity to analgesics, antipyretics, or NSAIDS (including celecoxib). Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis, lumiracoxib, celecoxib, cyclooxygenase-2 inhibitors</keyword>
</DOC>